Journal of Carcinogenesis & Mutagenesis

Akira Matsushita

Publications

• Research Article
  A Pilot Study- Neoadjuvant Chemotherapy with Gemcitabine and S1 in Patients with Resectable and Borderline Resectable Pancreatic Cancer
  Author(s): Akira Matsushita, Yoshiharu Nakamura, Hiroki Sumiyoshi, Takayuki Aimoto, Tadashi Yokoyama and Eiji UchidaAkira Matsushita, Yoshiharu Nakamura, Hiroki Sumiyoshi, Takayuki Aimoto, Tadashi Yokoyama and Eiji Uchida
  
  Introduction: Combination chemotherapy with gemcitabine and S-1 (GS) in metastatic advanced pancreatic cancer patients is superior to gemcitabine alone in response rate and progression free survival. We investigated this combination chemotherapy as neoadjuvant therapy for resectable and borderline resectable pancreatic cancer. Methods: Eleven patients with resectable or borderline resectable pancreatic cancer were administered to neoadjuvant chemotherapy with GS (NeoGS) from June 2011 to March 2013 at Nippon Medical School, and shortterm outcome was evaluated. Results: The median age was 69.1 years. According to NCCN criteria, 6 patients were resectable diseases and 5 were borderline resectable diseases. All patients received Neo GS with a median cycle of 3.5 (range: 2-11). No serious adverse events including death or .. View More»
  DOI: 10.4172/2157-2518.S9-006

  Abstract PDF